Психосоциальная реабилитация
Количество литературы, посвященной психосоциальным методам помощи онкологическим
больным, возросло. Авторы указывают на необходимость приспособления психотерапии к
специфическому контексту онкологии (Bloch и Kissane, 2000), а также создания новых подходов
для работы со специфическими проблемами, возникающими в связи с раком. Уже сделаны
важные шаги в разработке психосоциальных вмешательств, ориентированных на запущенные
стадии болезни. В рамках этих состояний существует необходимо помогать пациентам
сохранить чувство собственного достоинства и развивать духовные аспекты, связанные с
приближением смерти (Breitbart, 2002; Chochinov et al., 2005).
В нескольких исследованиях показано, что психологические вмешательства могут
способствовать значительному улучшению качества жизни пациентов, а также уменьшению
выраженности эмоциональных симптомов, включая депрессию и дезадаптивные стили
преодоления стресса (отчаяние, тревожная озабоченность) (Sheard и Maguire, 1999). Точная
постановка диагноза и направление на подходящее психологическое вмешательство
необходимы для повышения вероятности «полезного эффекта» и снижения процента
отказавшихся от лечения. Психотерапия (в индивидуальном или групповом формате)
продемонстрировала наибольшую эффективность у больных раком с выраженными
симптомами депрессии, в то время как психотерапевтическая работа с пациентами, имеющими
«нормальный» уровень психологического дистресса, почти не эффективна (Coyne et al., 2006;
Fawzy et al., 1995).
Ранее предполагалось, что психотерапевтические вмешательства могут влиять на увеличение
продолжительности жизни больных раком (Spiegel et al., 1989). Однако в более поздних
исследованиях это предположение не подтвердилось, и никакого влияния психотерапии на
улучшение прогноза у больных раком обнаружено не было (Goodwin et al., 2001; Kissane et al.
2007; Spiegel et al., 2007).
В качестве общей рекомендации, вариантом выбора лечения депрессии у больных раком
является комбинация психологического воздействия и психофармакотерапии, подобранная в
соответствии с потребностями каждого конкретного пациента. Некоторые авторы связывают
положительную динамику в лечении психических заболеваний, особенно депрессий, с
наличием у клиницистов инструментов скрининга, правильной диагностики, а также
психологического и психофармакологического аспектов помощи (Akechi et al., 2007; Sharpe et
al., 2004). О схожих результатах сообщается и в связи с применением недавно разработанных
NCCN руководств, предназначенных для проведения поддерживающей терапии при
расстройствах настроения (Holland и Bultz, 2007; NCCN, 2008).
- 97 -
ВЫВОДЫ
Депрессия — важное коморбидное психическое расстройство, сопровождающее рак. Недавний
отчет Института медицины Национальной академии наук, «Всеобъемлющий уход за больным
раком: знакомство с психосоциальными аспектами здоровья», является важным ориентиром
для принятия мер в отношении депрессии и тревоги, которые часто развиваются у
онкологических больных (Комитет психосоциального обслуживания больных раком и их семей
в общественных учреждениях, 2007). В этом отчете приведена программа стандартных
мероприятий по психосоциальной поддержке больных раком. Важно, чтобы психиатры
работали вместе со своими коллегами и способствовали выработке наиболее эффективных
практических методик для скрининга и выявления депрессий и других психиатрических
проблем у пациентов, получающих лечение в онкологических учреждениях. Ко всему прочему,
необходимо проведение доказательных клинических исследований, направленных на
определение оптимальных методов лечения депрессии на всех стадиях заболевания и при всех
видах рака. По мере того, как разрабатываются новые технологии и более мощные
химиотерапевтические и не‐химиотерапевтические способы подвергаются клиническим
исследованиям, нам необходимо расширять свое понимание того, как это лечение влияет на
психиатрическое обслуживание пациентов и их семей.
- 98 -
СПИСОК ЛИТЕРАТУРЫ
Adams F, Quesada JR, Gutterman JU.
Neuropsychiatric manifestations of human
leukocyte interferon therapy in patients
with cancer. JAMA 1 984;252:938‐41.
Akechi T, Nakano T, Akizuki N, et al. Somatic
symptoms for diagnosing major
depression in cancer patients.
Psychosomatics 2003;44:244‐8.
Akechi T, Taniguchi K, Suzuki S, et al.
Multifaceted psychosocial intervention
program for breast cancer patients after
first recurrence: Feasibility study.
Psychooncology 2007;16:517‐24.
Akizuki N, Yamawaki S, Akechi T, et al.
Development of an Impact Thermometer
for use in combination with the Distress
Thermometer as a brief screening tool for
adjustment disorders and/or major
depression in cancer patients. J Pain
Symptom Manage 2005;29:91‐9.
Baile WF, Buckman R, Lenzi R, et al. SPIKES‐A
six‐step protocol for delivering bad news:
Application to the patient with cancer.
Oncologist 2000;5:302‐11.
Bloch S, Kissane D. Psychotherapies in psycho‐
oncology. An exciting new challenge. Br J
Psychiatry 2000;177:112‐6.
Boyd AD, Riba M. Depression and pancreatic
cancer. J Natl Compr Canc Netw
2007;5:113‐6.
Breitbart W, ed. The IPOS "pocket" handbook
of palliative care for the psycho‐
oncologist. IPOS Press, International
Psycho‐Oncology Society 2007 (www.ipos-
Breitbart W, Rosenfeld B, Pessin H, et al.
Depression, hopelessness, and desire for
hastened death in terminally ill patients
with cancer. JAMA 2000; 284:2907‐11.
Breitbart W. Spirituality and meaning in
supportive care: Spirituality‐ and meaning‐
centered group psychotherapy
interventions in advanced cancer. Support
Care Cancer 2002;10:272‐80.
Carney CP, Jones L, Woolson RF, et al.
Relationship between depression and
pancreatic cancer in the general
population. Psychosom Med
2003;65:884‐8.
Carroll JK, Kohli S, Mustian KM, et al.
Pharmacologic treatment of cancer‐
related fatigue. Oncologist 2007;12:43‐51.
Chaturvedi SK, Maguire P, Hopwood P.
Antidepressant medications in cancer
patients. Psychooncology 1995;3:57‐60.
Chochinov H, Wilson K, Enns M, et al. Are you
depressed? Screening for depression in
the terminally ill. Am J Psychiatry
1997;154:674‐6.
Chochinov HM, Hack T, Hassard T, et al.
Dignity therapy: A novel
psychotherapeutic intervention for
patients near the end of life. J Clin Oncol
2005;23:5520‐5.
Chochinov HM. Depression in cancer patients.
Lancet Oncol 2001;2:499‐505.
Clarke DM, Kissane DW, Trauer T, et al.
Demoralization, anhedonia and grief in
society.org).
- 99 -
patients with severe physical illness.
World Psychiatry 2005;4:96‐105.
Committee on Psychosocial Services to Cancer
Patients/ Families in a Community Setting,
Adler NE, Page AEK, eds. Cancer care for
the whole patient: Meeting psychosocial
health needs. Washington, DC: The
National Academies Press (Institute of
Medicine); October, 2007 (www.nap.
edu/catalog.php?record id=11993).
Couper JW, Bloch S, Love A, et al. The
psychosocial impact of prostate cancer on
patients and their partners. Med J Aust
2006;185:428‐32.
Coyne JC, Lepore SJ, Palmer SC. Efficacy of
psychosocial interventions in cancer care:
Evidence is weaker than it first looks. Ann
Behav Med 2006;32:104‐10.
Derogatis LR, Morrow GR, Fetting J, et al. The
prevalence of psychiatric disorders among
cancer patients. JAMA 1983;249:751‐7.
De Sloover Koch Y, Ernst ME. Selective
serotonin‐reuptake inhibitors for the
treatment of hot flashes. Ann
Pharmacother 2004;38:1293‐6.
Endicott J. Measurement of depression in
patients with cancer. Cancer
1984;53:2243‐9.
Fallowfield L, Jenkins V. Current concepts of
communication skills training in oncology.
Recent Results Cancer Res
2006;168:105‐12.
Fawzy FI, Fawzy NW, Arndt LA, et al. Critical
review of psychosocial interventions in
- 100 -
cancer care. Arch Gen Psychiatry
1995;52:100‐13.
Fisch MJ, Loehrer PJ, Kristeller J, et al.
Fluoxetine versus placebo in advanced
cancer outpatients: A double‐blinded trial
of the Hoosier Oncology Group. J Clin
Oncol 2003;21:1937‐43.
Gil F, Grassi L, Travado L, et al. Use of distress
and depression thermometers to measure
psychosocial morbidity among southern
European cancer patients. Support Care
Cancer 2005;13:600‐6.
Goodwin PJ, Leszcz M, Ennis M, et al. The
effect of group psychosocial support on
survival in metastatic breast cancer. N
Engl J Med 2001;345:1719‐26.
Grassi L, Rosti G. Psychiatric and psychosocial
concomitants of abnormal illness
behaviour in patients with cancer.
Psychother Psychosom 1996;65:246‐52.
Grassi L. Uchitomi Y. Depression and
depressive disorders in cancer patients. In:
Johansen C, Grassi L, Costa A eds. Online
multilingual core‐curriculum in
psychosocial aspects of cancer care.
International Psycho‐Oncology Society,
IPOS, 2006 (available at: http://www.ipos-
society.org/ professionals/meetings‐
ed/ed‐online‐lectures.htm, accessed
August 28, 2008).
Grassi L, Biancosino B, Marmai L, et al. Effect
of reboxetine on major depressive
disorder in breast cancer patients: An
open‐label study. J Clin Psychiatry
2004;65:515‐20.
Grassi L, Holland JC, Johansen C, et al.
Psychiatric concomitants of cancer,
screening procedures, and training of
health care professionals in oncology: The
paradigms of psycho‐oncology in the
psychiatry field. In: Christodoulou GN, Ed.
Advances in Psychiatry, Second Volume.
World Psychiatric Association:
2005a. 59‐66.
Grassi L, Malacarne P, Maestri A, et al.
Depression, psychosocial variables and
occurrence of life events among patients
with cancer. J Affect Disord
1997;44:21‐30.
Grassi L, Mangelli L, Fava GA, et al.
Psychosomatic characterization of
Adjustment Disorders in the medical
setting. Some suggestions for DSM‐V. J
Affect Disord 2007;101:251‐4.
Grassi L, Rosti G, Lasalvia A, et al. Psychosocial
variables associated with mental
adjustment to cancer. Psychooncology
1993;2:11‐20.
Grassi L, Sabato S, Rossi E, et al. The use of
the Diagnostic Criteria for Psychosomatic
Research (DCPR) in oncology. Psychother
Psychosoma 2005b;74:100‐7.
Greaves MW. Itch in systemic disease:
Therapeutic options. Dermatol Ther
2005;18:323‐7.
Hjerl K, Andersen EW, Keiding N, et al.
Depression as a prognostic factor for
breast cancer mortality. Psychosomatics
2003;44:24‐30.
Heaven CM, Maguire P. The psychological
impact of cancer on patients' partners and
- 101 -
other key relatives: A review. Eur J Cancer
2003;39:1517‐24.
Hem E, Loge JH, Haldorsen T, et al. Suicide risk
in cancer patients from 1960 to 1999. J
Clin Oncol 2004;22:4209‐16.
Hewitt M, Rowland JH. Mental health service
use among adult cancer survivors: Analysis
of the National Health Interview Survey. J
Clin Oncol 2002;20:4581‐90.
Holland J.C. History of psycho‐oncology:
overcoming attitudinal and conceptual
barriers. Psychosom Med.
2002;64:206‐221.
Holland JC, Andersen B, Breitbart WS, et al.
NCCN. Distress management. J Natl Compr
Canc Netw 2007;5:66‐98.
Holland JC, Bultz BD. National comprehensive
Cancer Network (NCCN). The NCCN
guideline for distress management: A case
for making distress the sixth vital sign. J
Natl Compr Canc Netw 2007;5:3‐7.
Holland JC, Greenberg DB, Hughes MK. eds.
Quick reference for oncology clinicians:
The psychiatric and psychological
dimensions of cancer symptom
management. Charlottesville: IPOS
Press; 2006.
Holland JC, Romano SJ, Heiligenstein JH, et al.
A controlled trial of fluoxetine and
desipramine in depressed women with
advanced cancer. Psychooncology.
1998;7:291‐300.
Homsi J, Walsh D, Nelson KA.
Psychostimulants in supportive care.
Support Care Cancer 2000;8:385‐97.
Jehn CF, Kuehnhardt D, Bartholomae A, et al.
Biomarkers of depression in cancer
patients. Cancer 2006;107:2723‐9.
Jenkins V, Fallowfield L, Solis‐Trapala I, et al.
Discussing randomised clinical trials of
cancer therapy: Evaluation of a Cancer
Research UK training programme. BMJ
2005;330(7488):400.
Jin Y, Desta Z, Stearns V, et al. CYP2D6
genotype, antidepressant use, and
tamoxifen metabolism during adjuvant
breast cancer treatment. J Natl Cancer Inst
2005;97:30‐9.
Kadan‐Lottick NS, Vanderwerker LC, Block SD,
et al. Psychiatric disorders and mental
health service use in patients with
advanced cancer: A report from the
coping with cancer study. Cancer
2005;104:2872‐81.
Kawase E, Karasawa K, Shimotsu S, et al.
Evaluation of a one‐question interview for
depression in a radiation oncology
department in Japan. Gen Hosp Psychiatry
2006;28:321‐2.
Kelsen DP, Portenoy RK, Thaler HT, et al. Pain
and depression in patients with newly
diagnosed pancreas cancer. J Clin Oncol
1995;13:748‐55.
Kim HF, Fisch MJ. Antidepressant use in
ambulatory cancer patients. Curr Oncol
Rep 2006;8:275‐81.
Kissane DW, Clarke DM, Street AF.
Demoralization syndrome. A relevant
psychiatric diagnosis for palliative care. J
Palliat Care 2001;17:12‐21.
Kissane DW, Grabsch B, Clarke DM, et al.
Supportive‐expressive group therapy for
women with metastatic breast cancer:
Survival and psychosocial outcome from a
randomized controlled trial.
Psychooncology 2007;16:277‐86.
Kissane DW, McKenzie DP, Bloch S. Family
coping and bereavement outcome. Palliat
Med 1997;11:191‐201.
Kissane DW, McKenzie M, McKenzie DP, et al.
Psychosocial morbidity associated with
patterns of family functioning in palliative
care: Baseline data from the Family
Focused Grief Therapy controlled trial.
Palliat Med 2003;17:527‐37.
Konuk N, Atasoy N, Atik L, et al. Open‐label
study of adjunct modafinil for the
treatment of patients with fatigue,
sleepiness, and major depression treated
with selective serotonin reuptake
inhibitors. Adv Ther 2006;23:646‐54.
Lawrie I, Lloyd‐Williams M, Taylor F. How do
palliative medicine physicians assess and
manage depression. Palliat Med
2004;18:234‐8.
Lloyd‐Williams M, Taylor F, Dennis M. Is
asking patients in palliative care, "Are you
depressed?" appropriate? Prospective
study. BMJ 2003;327:372‐3.
Mangelli L, Fava GA, Grandi S, et al. Assessing
demoralization and depression in the
setting of medical disease. J Clin
Psychiatry 2005;66:391‐4.
Massie MJ. Prevalence of depression in
patients with cancer. J Natl Cancer Inst
Monogr 2004;32:57‐71.
- 102 -
McClain CS, Rosenfeld B, Breitbart W.: Effect
of spiritual well‐being on end‐of‐life
despair in terminally‐ill cancer patients
Lancet. 2003 ;361:1603‐1607.
Mermelstein HT, Lesko L. Depression in
patients with cancer. Psychooncology
1992;1:199‐215.
Middelboe T, Ovesen L, Mortensen EL, Bech
P.: Depressive symptoms in cancer
patients undergoing chemotherapy: a
psychometric analysis.Psychother
Psychosom. 1994;61:171‐177.
National Comprehensive Cancer Network.
NCCN Clinical Practice Guidelines in
Oncology™. Distress management‐NCCN,
2008 (available at http://www.nccn.org/
professionals/physician gls/f
guidelines.asp, accessed on August 29,
2008).
Newell SA, Sanson‐Fisher RW, Savolainen NJ.
Systematic review of psychological
therapies for cancer patients: Overview
and recommendations for future research.
J Natl Cancer Inst 2002;94:558‐84.
O'Mahony S, Goulet J, Kornblith A, et al.
Desire for hastened death, cancer pain
and depression: Report of a longitudinal
observational study. J Pain Symptom
Manage 2005;29:446‐57.
Onitilo AA, Nietert PJ, Egede LE. Effect of
depression on all‐cause mortality in adults
with cancer and differential effects by
cancer site. Gen Hosp Psychiatry
2006;28:396‐402.
Orr K, Taylor D. Psychostimulants in the
treatment of depression : A review of the
evidence. CNS Drugs 2007;21:239‐57.
Pae CU, Kim YJ, Won WY, et al. Paroxetine in
the treatment of depressed patients with
haematological malignancy: An open‐label
study. Hum Psychopharmacol.
2004;19:25‐9.
Parker PA, Baile WF, de Moor C, et al.
Psychosocial and demographic predictors
of quality of life in a large sample of
cancer patients. Psychooncology
2003;12:183‐93.
Pirl WF. Evidence report on the occurrence,
assessment, and treatment of depression
in cancer patients. J Natl Cancer Inst
Monographs 2004;32:32‐9.
Raison C, Miller AH. Depression in cancer:
New developments regarding diagnosis
and treatment. Biol Psychiatry
2003;54:283‐94.
Reiche EM, Morimoto HK, Nunes SM. Stress
and depression‐induced immune
dysfunction: Implications for the
development and progression of cancer.
Int Rev Psychiatry 2005;17:515‐27.
Rodin G, Lloyd N, Katz M, et al. Supportive
care guidelines group of cancer care
Ontario program in evidence‐based care.
The treatment of depression in cancer
patients: A systematic review. Support
Care Cancer 2007;15:123‐36.
Rodin G, Voshart K. Depression in the
medically ill: An overview. Am J Psychiatry
1986;143:696‐705.
- 103 -
Schwartz L, Lander M, Chochinov HM. Current
management of depression in cancer
patients. Oncology 2002;16:1102‐10
Sellick SM, Crooks DL. Depression and cancer:
An appraisal of the literature for
prevalence, detection, and practice
guideline development for psychological
interventions. Psychooncology
1999;8:315‐33.
Sharpe M, Strong V, Allen K, et al. Major
depression in outpatients attending a
regional cancer centre: Screening and
unmet treatment needs. Br J Cancer
2004;90:314‐20.
Sharpe M, Strong V, Allen K, et al.
Management of major depression in
outpatients attending a cancer centre: A
preliminary evaluation of a
multicomponent cancer nurse‐delivered
intervention. Br J Cancer 2004;90:310‐3.
Sheard T, Maguire P. The effect of
psychological interventions on anxiety and
depression in cancer patients: Results of
two meta‐analyses. Br J Cancer
1999;80:1770‐80.
Soygur H, Palaoglu O, Akarsu ES, et al.
Interleukin‐6 levels and HPA axis
activation in breast cancer patients with
major depressive disorder. Prog
Neuropsychopharmacol Biol Psychiatry
2007;31:1242‐7.
Spiegel D, Bloom JR, Kraemer HC, et al. Effect
of psychosocial treatment on survival of
patients with metastatic breast cancer.
Lancet 1989;2:888‐91.
Spiegel D, Butler LD, Giese‐Davis J, et al.
Effects of supportive‐expressive group
therapy on survival of patients with
metastatic breast cancer : A randomized
prospective trial. Cancer 2007;110:1130‐8.
Spiegel D, Giese‐Davis J. Depression and
cancer: Mechanisms and disease
progression. Biol Psychiatry 2003;
54:269‐82.
Spiegel D, Sands S, Koopman C. Pain and
depression in patients with cancer. Cancer
1994;74:2570‐8.
Theobald DE, Kirsh KL, Holtsclaw E, et al. An
open label pilot study of citalopram for
depression and boredom in ambulatory
cancer patients. Palliat Support Care
2003;1:71‐7.
Torta R, Berra C, Binaschi L, et al. Amisulpride
in the short‐term treatment of depressive
and physical symptoms in cancer patients
during chemotherapies. Support Care
Cancer 2007;15:539‐46.
Torta R, Siri I, Caldera P. Sertraline
effectiveness and safety in depressed
oncological patients. Support Care Cancer
2008;16:83‐91.
Uchitomi Y, Kugaya A, Akechi T, et al. Three
sets of diagnostic criteria for major
depression and correlations with
serotonin‐induced platelet calcium
mobilization in cancer patients.
Psychopharmacology 2001;153:244‐8.
Valentine AD. Cancer pain and depression:
Management of the dual‐diagnosed
patient. Curr Pain Headache Rep 2003
7:262‐9.
- 104 -
Van der Lee ML, van der Bom JG, Swarte NB,
et al. Euthanasia and depression: A
prospective cohort study among
terminally ill cancer patients. J Clin Oncol
2005;23:6607‐12.
von Ammon Cavanaugh S. Depression in the
medically ill. Critical issues in diagnostic
assessment. Psychosomatics
1995;36:48‐59.
Walker LG, Heys SD, Walker MB, et al.
Psychological factors can predict the
response to primary chemotherapy in
patients with locally advanced breast
cancer. Eur J Cancer 1999;35:1783‐8.
Watson M, Haviland JS, Greer S, et al.
Influence of psychological response on
survival in breast cancer: A population‐
based cohort study. Lancet
1999;354:1331‐6.
Watson M, Homewood J, Haviland J, et al.
Influence of psychological response on
breast cancer survival: 10‐year follow‐up
of a population‐based cohort. Eur J Cancer
2005;41:1710‐4.
- 105 -
Williams S, Dale J. The effectiveness of
treatment for depression/depressive
symptoms in adults with cancer: A
systematic review. Br J Cancer
2006;94:372‐90.
Wilson KG, Chochinov HM, McPherson CJ, et
al. Desire for euthanasia or physician‐
assisted suicide in palliative cancer care.
Health Psychol 2007;26:314‐23.
World Health Organization.
http://www.who.int/
mediacentre/factsheets/fs297/en/.2006.
Yoshikawa E, Matsuoka Y, Yamasue H, et al.
Prefrontal cortex and amygdala volume in
first minor or major depressive episode
after cancer diagnosis. Biol Psychiatry
2006;59:707‐12.
Zabora J, BrintzenhofeSzoc K, Curbow B, et al.
The prevalence of psychological distress
by cancer site. Psychooncology
2001;10:19‐28.
Глава 7